Migraine

Active Ingredient: Dihydroergotamine

Indication for Dihydroergotamine

Population group: only adults (18 - 65 years old)
Therapeutic intent: Curative procedure

Acute treatment of migraine headaches with or without aura.

For this indication, competent medicine agencies globally authorize below treatments:

1 tablet of 2.5 mg twice daily

For:

Dosage regimens

Oral, 2.5 milligrams dihydroergotamine, 2 times daily. The maximum allowed total dose is 10 milligrams dihydroergotamine daily.

2 mg in 2 divided doses daily

For:

Dosage regimens

Nasal, in total 2 milligrams dihydroergotamine, 4 doses in total, over the duration of 1 hour.

Detailed description

In clinical trials, dihydroergotamine mesylate has been effective for the acute treatment of migraine headaches with or without aura.

One spray (0.5 mg) of dihydroergotamine mesylate nasal spray should be administered in each nostril. Fifteen minutes later, an additional one spray (0.5 mg) of dihydroergotamine mesylate should be administered in each nostril, for a total dosage of four sprays (2 mg) of dihydroergotamine mesylate.

Studies have shown no additional benefit from acute doses greater than 2 mg for a single migraine administration. The safety of doses greater than 3 mg in a 24 hour period and 4 mg in a 7 day period has not been established.

1 ml that can be repeated at 1 hour intervals

For:

Dosage regimens

Regimen A: Intramuscular, 1 milliliters dihydroergotamine, once hourly, 1 to 3 doses in total.

Regimen B: Subcutaneous, 1 milliliters dihydroergotamine, once hourly, 1 to 3 doses in total.

Regimen C: Intravenous, 1 milliliters dihydroergotamine, once hourly, 1 to 2 doses in total.

Detailed description

Dihydroergotamine should be administered in a dose of 1 mL intravenously, intramuscularly or subcutaneously. The dose can be repeated, as needed, at 1 hour intervals to a total dose of 3 mL for intramuscular or subcutaneous delivery or 2 mL for intravenous delivery in a 24 hour period. The total weekly dosage should not exceed 6 mL.

Dihydroergotamine mesylate injection, should not be used for chronic daily administration.

Active ingredient

Dihydroergotamine

Dihydroergotamine binds with high affinity to 5-HT1DĪ± and 5-HT1DĪ² receptors. It also binds with high affinity to serotonin 5-HT1A, 5-HT2A, and 5-HT2C receptors. The therapeutic activity of dihydroergotamine in migraine is generally attributed to the agonist effect at 5-HT1D receptors.

Read more about Dihydroergotamine

Related medicines

Develop a tailored medication plan for your case, considering factors such as age, gender, and health history

Ask the Reasoner

Liability Disclaimer : RxReasoner has utilized reasonable care in providing content and services that are accurate, complete and up to date. However, RxReasoner does not accept any responsibility or liability about it. The content and services of RxReasoner are for informational purposes only and they are not intended to be a substitute for the knowledge, expertise, skill, and judgment of physicians, pharmacists, nurses, or other healthcare professionals involved in patient care. RxReasoner offers no medical advice. Users are responsible for the use of the provided content. A shown indication or treatment should not be construed to indicate that the medication is safe, appropriate, or effective in any given patient or under any particular circumstances. The absence of an indication or treatment should not roule out the existence of other appropriate medications. Always seek the advice of a physician or other qualified health provider with any questions you may have regarding a medical condition or medicament. RxReasoner is not liable for any damages allegedly sustained arising out of the use of its content and services.